Premium
Plasma leukocyte cell‐derived chemotaxin 2 is associated with the severity of systemic inflammation in patients with sepsis
Author(s) -
Ando Kazuyoshi,
Kato Hidehito,
Kotani Toru,
Ozaki Makoto,
Arimura Yutaka,
Yagi Junji
Publication year - 2012
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.2012.00488.x
Subject(s) - sepsis , inflammation , systemic inflammation , medicine , intensive care unit , white blood cell , c reactive protein , leukocyte counts , interleukin 6 , gastroenterology , immunology , systemic inflammatory response syndrome
ABSTRACT The aim of the present study was to determine the correlations between leukocyte cell‐derived chemotaxin 2 (LECT2) and inflammation‐related variables in human inflammatory disease. Plasma samples from 23 septic patients who had been admitted to the intensive care unit (ICU) of our institution and 31 volunteers were used. Plasma LECT2 concentrations were examined retrospectively and compared with those of various inflammatory cytokines and routine laboratory data. The LECT2 concentrations of the septic patients at the time of ICU entry (5.3 ± 4.1 ng/mL) were significantly lower than those of the volunteers (19.7 ± 3.4 ng/mL) and these concentrations had significantly increased by the time of ICU discharge. Individual analyses showed that the LECT2 concentrations of all 19 patients had increased by the time of ICU discharge. A combination of LECT2 and C‐reactive protein (CRP) concentrations was capable of discriminating the acute and recovery phases of sepsis to a degree similar to those of the combinations of CRP concentration and percentage of neutrophils, CRP concentration and percentage of immature white blood cells, or CRP and interleukin‐6 concentrations. Thus, the LECT2 concentration correlates with the severity of systemic inflammation in patients with sepsis. LECT2 may be a reliable diagnostic indicator of human inflammatory diseases.